S 49076

Drug Profile

S 49076

Alternative Names: S49076

Latest Information Update: 21 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Servier
  • Class Antineoplastics
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto oncogene protein c met inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glioblastoma; Non-small cell lung cancer
  • Preclinical Hepatocellular carcinoma

Most Recent Events

  • 03 Nov 2016 Servier completes a phase-I/II trial in Glioblastoma (Second-line therapy or greater, Recurrent, Combination therapy, Late-stage disease) in France and Switzerland (PO) (ISRCTN11619481)
  • 14 Apr 2016 Preclinical trials in Hepatocellular carcinoma in France (unspecified route) before April 2016
  • 14 Apr 2016 Pharmacodynamics data from preclinical studies in Hepatocellular carcinoma presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top